MHRA authorises Vumerity for multiple sclerosis patients
Vumerity is a next-generation oral fumarate treatment for adults with relapsing-remitting multiple sclerosis
Read More
Tag: Vumerity
Biogen & Alkermes get NDA for MS drug
The FDA has accepted the New Drug Application (NDA) for Biogen & Alkermes’ Diroximel Fumarate in multiple sclerosis (MS).
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
